☰

Yahao Bu, Ph.D. - Publications

Affiliations: 
2007 Roswell Park - Cellular and Molecular Biology State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Cell Biology
Tree Info Grants Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Cutler MJ, Belko KE, Bu Y, Verone-Boyle AR, Cutler D, Chan W, Kwan R, Lau JY, Smolinski MP. Abstract 4717: Effective preclinical management of angiosarcoma with oral paclitaxel Cancer Research. 79: 4717-4717. DOI: 10.1158/1538-7445.Am2019-4717  0.349
2018 Smolinski MP, Bu Y, Clements J, Gelman IH, Hegab T, Cutler DL, Fang JWS, Fetterly G, Kwan R, Barnett A, Lau JYN, Hangauer DG. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). Journal of Medicinal Chemistry. PMID 29617135 DOI: 10.1021/Acs.Jmedchem.8B00164  0.573
2016 Gao Z, Bu Y, Liu X, Wang X, Zhang G, Wang E, Ding S, Liu Y, Shi R, Li Q, Fu J, Yu Z. TCDD promoted EMT of hFPECs via AhR, which involved the activation of EGFR/ERK signaling. Toxicology and Applied Pharmacology. PMID 26971374 DOI: 10.1016/j.taap.2016.03.005  0.363
2012 Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Molecular Cancer Therapeutics. 11: 1936-47. PMID 22784709 DOI: 10.1158/1535-7163.MCT-12-0146  0.32
2011 Fallah-Tafti A, Foroumadi A, Tiwari R, Shirazi AN, Hangauer DG, Bu Y, Akbarzadeh T, Parang K, Shafiee A. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. European Journal of Medicinal Chemistry. 46: 4853-8. PMID 21852023 DOI: 10.1016/J.Ejmech.2011.07.050  0.306
2011 Bu Y, Gao L, Gelman IH. Role for transcription factor TFII-I in the suppression of SSeCKS/Gravin/Akap12 transcription by Src. International Journal of Cancer. Journal International Du Cancer. 128: 1836-42. PMID 20568114 DOI: 10.1002/Ijc.25524  0.613
2010 Su B, Bu Y, Engelberg D, Gelman IH. SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway. The Journal of Biological Chemistry. 285: 4578-86. PMID 20018890 DOI: 10.1074/Jbc.M109.073494  0.644
2010 Bu Y, Gao L, Hangauer D, Gelman IH. Abstract 2534: Suppression of prostate cancer growth by the Src signaling inhibitor, KXO1 (KX2-391) Cancer Research. 70: 2534-2534. DOI: 10.1158/1538-7445.Am10-2534  0.621
2010 Bu Y, Smolinski M, Qu J, Kazim L, Gelman I, Dyster L, Hangauer D. Abstract 2487: Mechanism of action KX01 (KX2-391), a novel tubulin polymerization and Src signaling inhibitor proceeding to Phase II clinical trials Cancer Research. 70: 2487-2487. DOI: 10.1158/1538-7445.Am10-2487  0.599
2009 Sachdev S, Bu Y, Gelman IH. Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion. Bmc Cancer. 9: 12. PMID 19138410 DOI: 10.1186/1471-2407-9-12  0.614
2007 Bu Y, Gelman IH. v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex. The Journal of Biological Chemistry. 282: 26725-39. PMID 17626016 DOI: 10.1074/Jbc.M702885200  0.564
2006 Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Research. 66: 5599-607. PMID 16740695 DOI: 10.1158/0008-5472.Can-05-4123  0.623
Show low-probability matches.